Kingdon Capital Management, L.L.C. Apellis Pharmaceuticals, Inc. Put Options Transaction History

Kingdon Capital Management, L.L.C.

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $8.95 Million - $13.9 Million	200,000 New	200,000 $13.7 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $5.26 Million - $8.88 Million	-150,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $5.32 Million - $8.12 Million	150,000 New	150,000 $7.62 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.54 Million - $2.46 Million	-50,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $1.57 Million - $3.49 Million	50,000 New	50,000 $1.65 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.